BridgeBio Pharma
BBIO
BBIO
250 hedge funds and large institutions have $4.43B invested in BridgeBio Pharma in 2024 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 106 increasing their positions, 73 reducing their positions, and 36 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
0.38% more ownership
Funds ownership: 93.11% → 93.49% (+0.38%)
14% less funds holding in top 10
Funds holding in top 10: 14 → 12 (-2)
18% less capital invested
Capital invested by funds: $5.42B → $4.43B (-$989M)
Holders
250
Holding in Top 10
12
Calls
$306M
Puts
$85.9M
Top Buyers
| 1 | +$50.2M | |
| 2 | +$32.2M | |
| 3 | +$27.6M | |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$25.3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.1M |
Top Sellers
| 1 | -$86.7M | |
| 2 | -$34.1M | |
| 3 | -$29.6M | |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$26.4M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$19.9M |